September 16, 2024

Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Fig. 6. One histologically representative picture of cPARP staining in control group versus IDRX-42₂5 treatment group in the experiment with UZLX-GIST9KIT11+17.

Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

Key Points

Abstract

Cite This Study